ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1584230
This article is part of the Research TopicResearch and Innovation Approaches to Personalized Pharmacotherapies for Respiratory DiseasesView all 7 articles
Correlation between metformin use and mortality in acute respiratory failure: a retrospective ICU cohort study
Provisionally accepted
- 1Department of Clinical Pharmacy, Shifang People's Hospital, Shifang, China
- 2Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, China
- 3People's Hospital of Zhongjiang County, Deyang, China
- 4Department of Pharmacy and Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The aim of this study was to investigate the association of metformin use with the risk of in-hospital mortality and prognosis in acute respiratory failure (ARF) patients admitted to the intensive care unit (ICU).We conducted a retrospective cohort study using the MIMIC-IV database.Patients were categorized into metformin and non-metformin groups based on medication exposure. Primary outcomes were in-hospital and ICU mortality, while 30day and 90-day all-cause mortality served as secondary endpoints. We applied Kaplan-Meier survival curves, Cox proportional hazards models, and logistic regression to assess associations. Propensity score matching (PSM) and machine learning algorithms were used for confounder adjustment and feature selection.Results: After PSM, 1,429 patients with ARF were included (374 metformin users; 1,055 non-users). Multivariate logistic regression revealed that metformin use was associated with significantly reduced in-hospital mortality (OR = 0.202, 95% CI: 0.123-0.317, p < 0.001) and ICU mortality (OR = 0.245, 95% CI: 0.142-0.399, p < 0.001). Cox models showed consistent reductions in 30-day (HR = 0.199, 95% CI: 0.124-0.320, p < 0.001) and 90-day (HR = 0.230, 95% CI: 0.150-0.352, p < 0.001) mortality. Kaplan-Meier curves confirmed better survival in the metformin group (p < 0.001). Subgroup analyses supported a consistent protective effect of metformin across most patient strata.Metformin use was significantly associated with decreased short-term mortality among ICU patients with ARF. These findings suggest that metformin, beyond its glucose-lowering effects, may offer survival benefits in critically ill populations. Clinicians should consider the potential role of metformin when managing ICU patients with type 2 diabetes and ARF. Further prospective studies are warranted to confirm these findings and optimize clinical application strategies.
Keywords: Intensive Care Unit, Acute Respiratory Failure, Retrospective cohort study, Mortality, Metformin
Received: 27 Feb 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Yang, Liu, Hou, Wei, Huang and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liang Huang, Department of Pharmacy and Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China
Wei Wei, Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.